DOCSLIB.ORG

Vitamin K and D Supplementation and Bone Health in Chronic Kidney Disease—Apart Or Together?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Vitamin K and D Supplementation and Bone Health in Chronic Kidney Disease—Apart Or Together? nutrients Review Vitamin K and D Supplementation and Bone Health in Chronic Kidney Disease—Apart or Together? Marta Ziemi ´nska 1, Beata Sieklucka 2 and Krystyna Pawlak 1,* 1 Department of Monitored Pharmacotherapy, Medical University of Bialystok, 15-222 Bialystok, Poland; [email protected] 2 Department of Pharmacodynamics, Medical University of Bialystok, 15-222 Bialystok, Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-85-748-5600 Abstract: Vitamin K (VK) and vitamin D (VD) deficiency/insufficiency is a common feature of chronic kidney disease (CKD), leading to impaired bone quality and a higher risk of fractures. CKD patients, with disturbances in VK and VD metabolism, do not have sufficient levels of these vitamins for maintaining normal bone formation and mineralization. So far, there has been no consensus on what serum VK and VD levels can be considered sufficient in this particular population. Moreover, there are no clear guidelines how supplementation of these vitamins should be carried out in the course of CKD. Based on the existing results of preclinical studies and clinical evidence, this review intends to discuss the effect of VK and VD on bone remodeling in CKD. Although the mechanisms of action and the effects of these vitamins on bone are distinct, we try to find evidence for synergy between them in relation to bone metabolism, to answer the question of whether combined supplementation of VK and VD will be more beneficial for bone health in the CKD population than administering each of these vitamins separately. Citation: Ziemi´nska,M.; Sieklucka, B.; Pawlak, K. Vitamin K and D Keywords: vitamin K; vitamin D; chronic kidney disease; bone remodeling; vitamin K and D Supplementation and Bone Health in supplementation Chronic Kidney Disease—Apart or Together? Nutrients 2021, 13, 809. https://doi.org/10.3390/nu13030809 1. Introduction Academic Editor: Chronic kidney disease (CKD) represents a global health issue involving about 13% Vassilios Liakopoulos of the general population, of which about 11% are patients in the 3–5 stage of CKD [1]. Impaired kidney function impacts the quality of bone tissue and results in the development Received: 28 January 2021 of disorders in bone and mineral metabolism, which are defined as Chronic Kidney Disease- Accepted: 24 February 2021 Published: 1 March 2021 Mineral Bone Disorders (CKD-MBD) [2]. Abnormalities in mineral and bone metabolism contribute, in part, to severity of vascular calcification (VC). In this context, CKD-specific Publisher’s Note: MDPI stays neutral risk factors are believed to drive substantially to VC and cardiovascular disease. It is also with regard to jurisdictional claims in established that patients with CKD stage 3–5 will die due to cardiovascular events before published maps and institutional affil- the need of renal replacement therapy [3,4]. iations. CKD-MBD impacts bone remodeling (Figure1)—the dynamic process mediated mainly by the two antagonistically acting cellular populations: osteoblasts (OBs) that control the formation of bone and osteoclasts (OCs), with the ability to resorb mineral- ized bone [5]. This process is tightly regulated by local and systemic hormones, such as parathyroid hormone (PTH), 1,25-dihydroxyvitamin D (1,25D), and vitamin K (VK) [5,6]. Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. The process of bone remodeling is composed of four phases: the activation phase (the This article is an open access article recruitment of OCs); the resorption phase (the resorption of bone by OCs); the reversal distributed under the terms and phase (the apoptosis of OCs and the recruitment of OBs); and the formation phase (the OBs conditions of the Creative Commons lay down new organic bone matrix that subsequently mineralize) [6]. Bone remodeling Attribution (CC BY) license (https:// together with bone size, geometry, structure, and volume determines bone’s biomechanical creativecommons.org/licenses/by/ properties, integrity, and strength, providing renewal of damaged bone. An imbalance 4.0/). between the amount of resorbed bone and the quantity of new bone formation substantially Nutrients 2021, 13, 809. https://doi.org/10.3390/nu13030809 https://www.mdpi.com/journal/nutrients Nutrients 2021, 13, x FOR PEER REVIEW 2 of 33 Nutrients 2021, 13, 809 2 of 34 imbalance between the amount of resorbed bone and the quantity of new bone formation contributessubstantially to thecontributes increased to risk the of fractures,increased whichrisk of is fractures, associated which with higher is associated mortality with in patientshigher mortality with CKD in [7 patients–9]. with CKD [7–9]. Figure 1. Bone remodeling. Abbreviations: ALP, alkaline phosphatase; BGLAP, bone-Gla-protein; Figure 1. Bone remodeling. Abbreviations: ALP, alkaline phosphatase; BGLAP, bone-Gla-protein; BMP, bone morphogenic protein; BSP, bone sialoprotein; c-fms, colony-stimulating factor-1 BMP, bone morphogenic protein; BSP, bone sialoprotein; c-fms, colony-stimulating factor-1 receptor; receptor; COL1, collagen type 1; CTSK, cathepsin K; HSC, hemapoietic stem cells; MAPKs, COL1,mitogen collagen-activated type protein 1; CTSK, kinases; cathepsin M-CSF, K; HSC, macrophage hemapoietic colony stem-stimulating cells; MAPKs, factor; mitogen-activated MMP-9, matric proteinmetalloproteinase kinases; M-CSF, 9; Msc, macrophage mesenchymal colony-stimulating stem cell; NFATc, factor; nuclear MMP-9, factor matric of activated metalloproteinase T-cells; NFkB, 9; Msc,nuclear mesenchymal factor-kappa stem B; cell; OPN, NFATc, osteopontin; nuclear factorOCPs, of osteoclast activated precursors; T-cells; NFkB, RANK, nuclear receptor factor-kappa activator B; OPN,of nuclear osteopontin; factor kappa OCPs, B; osteoclast RANKL, precursors; receptor activator RANK, of receptor nuclear activator factor kappa of nuclear B ligand; factor Runx2, kappa B; RANKL,runt-related receptor transcription activator of factor nuclear 2; TRAF6, factor kappa Tumor B ligand;necrosis Runx2, factor runt-related receptor associated transcription factor factor 6; 2; TRAF6,TRAP, Tumortartare necrosis-resistant factor acid phosphatase. receptor associated factor 6; TRAP, tartare-resistant acid phosphatase. ManyMany clinical clinical studies studies reported reported on VKon VK and and vitamin vitamin D (VD) D (VD) deficiency deficiency in patients in patients with CKDwith or CKD undergoing or undergoing dialysis dialysis [3,10–12 [3,10]. These–12]. vitaminThese vitamin deficiencies deficiencies could resultcould fromresult both from dietaryboth dietary and nondietary and nondietary determinants. determinants Dietary. Dietary recommendations recommendation for CKDs for patients, CKD suchpatients, as dietssuch low as diets in potassium low in potassium (fewer leafy (fewer green leafy vegetables green vegetables rich in vitamin rich in K1,vitamin VK1) K1 and, VK1) low and in phosphatelow in phosphate (fewer dairy (fewer products dairy products rich in vitamin rich in vitamin K2, VK2) K2 could, VK2) promote could promote VK deficiency. VK de- Holdenficiency. et Holden al. [3] showed et al. [ that3] showed patients that with patients stage 3–5with CKD stage have 3–5 higher CKD VK1have levelshigher than VK1 thoselevels on than maintenance those on maintenance dialysis. They dialysis. concluded They that concluded patients that who patients were clinically who were better clini- nourishedcally better have nourished also better have vitamin also better K status. vitamin Nutritional K status. factors Nutritional may alsofactors affect may the also defi- af- ciencyfect the of VDdeficiency status in of CKD. VD status The low in foodCKD. intake The low was food frequently intake noticed was frequently in this population, noticed in duethis to population, numerous due reasons, to numerous such as reduced reasons, appetite, such as reduced dietaryrestrictions, appetite, dietary i.e., low restrictions, protein andi.e., phosphate low protein diets, and uremic-related phosphate diets, gastrointestinal uremic-related symptoms, gastrointestinal and impaired symptoms gastrointesti-, and nalimpaired absorption gastrointestinal of VD [13]. The absorption nondietary of VD determinants [13]. The nondietary of VD in a determinants cohort of patients of VD with in a CKDcohort included of patients age, gender,with CKD low included physical age, activity, gender, less sunlightlow physical exposure, activity, blunted less sunlight the re- sponseexposure, of plasma blunted VD the to ultravioletresponse of (UVB) plasma irradiation, VD to ultraviolet and hyperpigmentation, (UVB) irradiation which, and may hy- playperpigmentation, a role in the impaired which may endogenous play a role VD in synthesis the impaired [14]. Additionally, endogenous withVD synthesis an increased [14]. lossAdditionally, of renal tissue, with the an availability increased loss and functionalityof renal tissue, of the 1-α availabilityhydroxylase and decreases, functionality thereby of reducing1-α hydroxylase 1,25D [15 decreases,]. Proteinuria thereby has alsoreducing been described1,25D [15] as. Proteinuria a contributing has factoralso been in the de- pathogenesisscribed as a contributing of VD deficiency facto [r3 ,in13 the,14]. pathogenesis Vitamin D binding of VD def proteiniciency (VDBP) [3,13,14] carries. Vitamin about D 85%binding of the protein circulating (VDBP) 25-hydroxyvitamin carries about 85% D (25D), of the VDBP–25Dcirculating complexes25-hydroxyvitamin are filtered D in (25D the), glomerulus. Patients
Load more

Recommended publications
  • Animal Models of Osteoporosis - Necessity and Limitations
    A.European Simon TurnerCells and Materials V ol. 1. 2001 (pages 66-81) DOI: 10.22203/eCM.v001a08 Running title: Animal models ISSN - osteoporosis 1473-2262 ANIMAL MODELS OF OSTEOPOROSIS - NECESSITY AND LIMITATIONS A. Simon Turner* Department of Clinical Sciences, Colorado State University, Ft. Collins, CO 80523, USA. Abstract Review of Animal Models of Osteoporosis There is a great need to further characterise the available General introduction to the need for animal models animal models for postmenopausal osteoporosis, for the Postmenopausal osteoporosis is a major health prob- understanding of the pathogenesis of the disease, investi- lem for women, the understanding of which is hindered by gation of new therapies (e.g. selective estrogen receptor the difficulty of studying a disease that is restricted to modulators (SERMs)) and evaluation of prosthetic devices humans. Osteoporosis is a slowly progressive disease, in osteoporotic bone. Animal models that have been used necessitating a study of several years’ duration to allow in the past include non-human primates, dogs, cats, ro- for a response to therapy. Because results come slowly, dents, rabbits, guinea pigs and minipigs, all of which have accumulation of data is time consuming, and maintenance advantages and disadvantages. Sheep are a promising of a study group is made more difficult by natural attrition model for various reasons: they are docile, easy to handle due to either relocation or death. and house, relatively inexpensive, available in large num- Lifestyle and health-related factors such as smoking, bers, spontaneously ovulate, and the sheep’s bones are alcoholism, and diet have been linked with an increased large enough to evaluate orthopaedic implants.
    [Show full text]
  • Preserved Bone Mass in Ovariectomized Rats Treated With
    Preserved bone mass in ovariectomized rats treated with parathyroid-hormone-related peptide (1-34) and (107-111) fragments J Rouffet, Veronique Coxam, N Gaumet, Jp Barlet To cite this version: J Rouffet, Veronique Coxam, N Gaumet, Jp Barlet. Preserved bone mass in ovariectomized rats treated with parathyroid-hormone-related peptide (1-34) and (107-111) fragments. Reproduction Nutrition Development, EDP Sciences, 1994, 34 (5), pp.473-481. hal-00899674 HAL Id: hal-00899674 https://hal.archives-ouvertes.fr/hal-00899674 Submitted on 1 Jan 1994 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Original article Preserved bone mass in ovariectomized rats treated with parathyroid-hormone-related peptide (1-34) and (107-111) fragments J Rouffet V Coxam N Gaumet JP Barlet1 1 INRA-Theix, Métabolisme Minéral, 63122 Saint-Genès-Champanelle, France; 2 Radiobiology Division, School of Medicine, University of Utah, Salt Lake City, UT 84112, USA (Received 28 April 1994; accepted 25 July 1994) Summary ― The effect of synthetic human PTHrP (1 -34) or (107-111) fragments on bone loss was stud- ied in rats, one month after ovariectomy (OVX). Four groups of 7-8-month-old rats were treated sc daily for 13 d with PTHrP (1-34) or (107-111 ) at the dose of 1 or 3 nmol/100 g body weight.
    [Show full text]
  • Effect of Chlorella Pyrenoidosa Protein Hydrolysate-Calcium
    marine drugs Article Effect of Chlorella Pyrenoidosa Protein Hydrolysate-Calcium Chelate on Calcium Absorption Metabolism and Gut Microbiota Composition in Low-Calcium Diet-Fed Rats Pengpeng Hua 1,2 , Yu Xiong 1, Zhiying Yu 1, Bin Liu 1,2,* and Lina Zhao 1,* 1 National Engineering Research Center of JUNCAO Technology, Fujian Agriculture and Forestry University, Fuzhou 350002, China; huapengpeng_fl[email protected] (P.H.); [email protected] (Y.X.); [email protected] (Z.Y.) 2 College of Food Sciences, Fujian Agriculture and Forestry University, Fuzhou 350002, China * Correspondence: [email protected] (B.L.); [email protected] (L.Z.); Tel.: +86-591-8353-0197 (B.L. & L.Z.) Received: 30 April 2019; Accepted: 3 June 2019; Published: 11 June 2019 Abstract: In our current investigation, we evaluated the effect of Chlorella pyrenoidosa protein hydrolysate (CPPH) and Chlorella pyrenoidosa protein hydrolysate-calcium chelate (CPPH-Ca) on calcium absorption and gut microbiota composition, as well as their in vivo regulatory mechanism in SD rats fed low-calcium diets. Potent major compounds in CPPH were characterized by HPLC-MS/MS, and the calcium-binding mechanism was investigated through ultraviolet and infrared spectroscopy. Using high-throughput next-generation 16S rRNA gene sequencing, we analyzed the composition of gut microbiota in rats. Our study showed that HCPPH-Ca increased the levels of body weight gain, serum Ca, bone activity, bone mineral density (BMD) and bone mineral content (BMC), while decreased serum alkaline phosphatase (ALP) and inhibited the morphological changes of bone. HCPPH-Ca up-regulated the gene expressions of transient receptor potential cation V5 (TRPV5), TRPV6, calcium-binding protein-D9k (CaBP-D9k) and a calcium pump (plasma membrane Ca-ATPase, PMCA1b).
    [Show full text]
  • Intestinal Microbiota: a Potential Target for the Treatment of Postmenopausal Osteoporosis
    OPEN Citation: Bone Research (2017) 5, 17046; :10.1038/boneres.2017.46 www.nature.com/boneres REVIEW ARTICLE Intestinal microbiota: a potential target for the treatment of postmenopausal osteoporosis Xin Xu1,2, Xiaoyue Jia1,2, Longyi Mo1, Chengcheng Liu1,3, Liwei Zheng1,4, Quan Yuan1,5 and Xuedong Zhou1,2 Postmenopausal osteoporosis (PMO) is a prevalent metabolic bone disease characterized by bone loss and structural destruction, which increases the risk of fracture in postmenopausal women. Owing to the high morbidity and serious complications of PMO, many efforts have been devoted to its prophylaxis and treatment. The intestinal microbiota is the complex community of microorganisms colonizing the gastrointestinal tract. Probiotics, which are dietary or medical supplements consisting of beneficial intestinal bacteria, work in concert with endogenous intestinal microorganisms to maintain host health. Recent studies have revealed that bone loss in PMO is closely related to host immunity, which is influenced by the intestinal microbiota. The curative effects of probiotics on metabolic bone diseases have also been demonstrated. The effects of the intestinal microbiota on bone metabolism suggest a promising target for PMO management. This review seeks to summarize the critical effects of the intestinal microbiota and probiotics on PMO, with a focus on the molecular mechanisms underlying the pathogenic relationship between bacteria and host, and to define the possible treatment options. Bone Research (2017) 5, 17046; doi:10.1038/boneres.2017.46;
    [Show full text]
  • Download PDF File
    Folia Morphol. Vol. 78, No. 4, pp. 789–797 DOI: 10.5603/FM.a2019.0035 O R I G I N A L A R T I C L E Copyright © 2019 Via Medica ISSN 0015–5659 journals.viamedica.pl Biochemical and immunohistochemical investigations on bone formation and remodelling in ovariectomised rats with tamoxifen citrate administration M. Baloğlu1, E. Gökalp Özkorkmaz2 1Department of Physiotherapy, Diyarbakir Gazi Yasargil Education and Research Hospital, Diyarbakir, Turkey 2Department of Histology and Embryology, Dicle University, School of Medicine, Diyarbakir, Turkey [Received: 31 January 2019; Accepted: 18 February 2019] Background: Osteoporosis results with the imbalance between osteoblastic for- mation and osteoclastic resorption, resulting in susceptibility to bone fractures. Ovariectomy leads to osteoporosis by triggering alterations in bone formation and structure. Tamoxifen as an anti-oestrogen is used for adjuvant therapy especially in metastatic diseases and known to have a bone mass protective effect after ovariectomy. Materials and methods: An animal model of ovariectomy induced osteoporosis after tamoxifen citrate administration was studied via biochemical and immuno- histochemical methods. Female Wistar albino rats (n = 45), selected according to their oestrous cycle, were divided into three groups; I — control, II — ovariec- tomy, III — ovariectomy + tamoxifen. Following ovariectomy, tamoxifen citrate (10 mg/kg) was given intraperitoneally daily for 8 weeks. At the end of the period, animals were sacrificed under anaesthesia, blood samples were taken to measure oestrogen, calcium, and alkaline phosphate. Tibia bone samples were fixed in formalin solution and decalcified with 5% ethylene-diamine tetra acetic acid. After the routine histological follow up, samples were embedded in paraffin and cut with a microtome for semi-thin sections.
    [Show full text]
  • Bone-Vol-122-13.Pdf
    Bone 122 (2019) 123–135 Contents lists available at ScienceDirect Bone journal homepage: www.elsevier.com/locate/bone Full Length Article Development and characterization of supramolecular calcitonin assembly and assessment of its interactions with the bone remodelling process T Kapil Manglania, Viji Vijayana, Chandramani Pathakb, Mayuri Khandelwala, Parminder Singhc, ⁎ Stalin Chellappaa, Vijay K. Yadavc, Avadhesha Suroliad, Sarika Guptaa, a Molecular Science Laboratory, National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi 110067, India b Cell Biology Laboratory, School of Biological Sciences and Biotechnology, Indian Institute of Advanced Research, Gandhinagar 382007, Gujarat, India c Metabolic Research Laboratory, National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi 110067, India d Molecular Biophysics Unit, Indian Institute of Sciences, Bengaluru 560012, Karnataka, India ARTICLE INFO ABSTRACT Keywords: Osteoporosis is the most common metabolic bone disease, which poses an immense socio-economic burden on Human calcitonin the society. Human calcitonin, though safe, is not considered as a therapeutic option because of its high tendency Protein aggregation to self-associate to form amyloid fibrils thereby affecting its potency. To circumvent this issue we harnessed the Ovariectomy inherent capacity of aggregation and developed an assemblage of human calcitonin monomers, [Supramolecular Osteoporosis Calcitonin Assembly (SCAeI)], which releases biologically active calcitonin monomers in a sustained manner for a period of at least three weeks. AFM and FT-IR analysis showed that SCA-I is amorphous aggregates of calcitonin monomers. Both SCA-I and monomer released from it demonstrated superior anti-osteoclast activity and pro- teolytic stability in-vitro. SCA-I upon single injection significantly improved bone formation markers and reduced bone resorption markers in ovariectomized (OVX) rat model of postmenopausal osteoporosis.
    [Show full text]
  • Loss of Cancellous Bone Mass and Connectivity in Ovariectomized Rats Can Be Restored by Combined Treatment with Parathyroid Hormone and Estradiol
    Loss of cancellous bone mass and connectivity in ovariectomized rats can be restored by combined treatment with parathyroid hormone and estradiol. V Shen, … , R Xu, R Lindsay J Clin Invest. 1993;91(6):2479-2487. https://doi.org/10.1172/JCI116483. Research Article To evaluate the potential use of a combination of antiresorption and bone formation-promoting agents as a treatment for postmenopausal osteoporosis, we examined the effects of combined and separate administration of estrogen (17 beta- estradiol, 30 micrograms/kg per d, s.c.) and parathyroid hormone (rPTH [1-34], 40 micrograms/kg per d, s.c.) on the proximal tibia of ovariectomized (Ovx) rats. The treatments lasted for 4 wk and were initiated 1, 3, and 5 wk after surgery. Ovx resulted in rapid loss of cancellous bone volume (Cn-BV/TV) as well as trabecular connectivity, as determined by two dimensional strut analysis. When administered in a preventive mode, treatment beginning 1 wk post-Ovx, estrogen or PTH treatment alone preserved Cn-BV/TV and trabecular connectivity, and combined estrogen and PTH treatment caused a 40% increment in Cn-BV/TV while maintaining comparable trabecular connectivity with that seen in the Sham- operated animals. When administered in a curative mode to rats with established osteoporosis, treatments beginning 3 or 5 wk post-Ovx, estrogen or PTH treatment alone prevented further loss of connectivity and Cn-BV/TV, whereas the combined treatment resulted in as much as a 300% improvement in one of the parameters of trabecular connectivity, node to node strut length, and a 106% increase in Cn-BV/TV, with respect to the bone status at the initiation of treatment.
    [Show full text]
  • An Estrogen Deficiency After Menopause Is Associated With
    J Nutr Sci Vitaminol, 50, 100-105, 2004 Estrogenic Effects of Sedum sarmentosum Bunge in Ovariectomized Rats Won-Bee KIM1,Yun-Ja PARK1, Mi-Ra PARK1, Tae-Yeul HA2, Sang-Hyeon LEE3,4, Song-Ja BAE1,3and Mihyang KIM1,3, * 1 Department of Food and Nutrition, Silla University, Boson 617-736, Korea 2Food Function Research Division, Korea FoodResearch Institute, Kyonggi463-746, Korea 3 Marine BiotechnologyCenter for Bio-Functional Material Industries, Busan 617-736, Korea 4Departrnent of Bioscienceand Biotechnology , Silla University, Busan 617-736, Korea (Received March 26, 2003) Summary The aim of this study was to evaluate the effects of Sedum sarmentosum Bunge (SS) on the lipid on serum and the collagen content of the connective tissues in ovariecto mized estrogen-deficient rats. Three groups were surgically ovariectomized. The fourth group was sham operated. From day 2 until day 37 after the ovariectomy, Sprague-Dawley female rats were randomly assigned to the following groups: sham-operated rats (sham), ovariectomized control rats (OVX-control), ovariectomized rats supplemented with an ethyl ether fraction of SS at 10mg/kg bw/d (OVX-EE), ovariectomized rats supplemented an ethyl acetate fraction of SS at 10mg/kg bw/d (OVX-EA). The SS fractions were orally adminis trated at 1mL per day. The estrogenic effects of the ethyl ether and ethyl acetate fractions of SS, were investigated using one in vitro assay and two in vivo assays. The treatment of the partition of the ethyl ether and ethyl acetate layers of SS increased the transcriptional activ ity 0.7-fold and 0.5-fold compared to those that were given 17ƒÀ-estradiol treatment, respec tively.
    [Show full text]
  • Overview: Animal Models of Osteopenia and Osteoporosis
    J Musculoskel Neuron Interact 2001; 1(3):193-207 Review Article Hylonome Overview: animal models of osteopenia and osteoporosis W.S.S. Jee, W. Yao Division of Radiobiology, Department of Radiobiology, University of Utah, School of Medicine, Salt Lake City, Utah, USA Abstract Prior to initiating a clinical trial in a post-menopausal osteoporosis study, it is reasonable to recommence the evaluation of treatment in the 9-month-old ovariectomized female rat. A female rat of this age has reached peak bone mass and can be manipulated to simulate clinical findings of post-menopausal osteoporosis. Ample time exists for experimental protocols that either prevent estrogen depletion osteopenia or restore bone loss after estrogen depletion. More time can be saved by acceleration of the development of the osteopenia by combining ovariectomized (OVX) plus immobilization (IM) models. Methods like serum biochemistry, histomorphometry and densitometry used in humans are applicable in rats. Like most animal models of osteopenia, the rat develops no fragility fractures, but mechanical testing of rat bones substitutes as a predictor of bone fragility. Recent studies have shown that the prevailing activity in cancellous and cortical bone of the sampling sites in rats is remodeling. The problems of dealing with a growing skeleton, the site specificity of the OVX and IM models, the lack of trabecular and Haversian remodeling and the slow developing cortical bone loss have been and can be overcome by adding beginning and pre-treatment controls and muscle mass measurements in all experimental designs, selecting cancellous bone sampling sites that are remodeling, concentrating the analysis of cortical bone loss to the peri-medullary bone and combining OVX and IM in a model to accelerate the development of both cancellous and cortical bone osteopenia.
    [Show full text]
  • Biological Effect of Calcium and Vitamin D Dietary Supplements Against Osteoporosis in Ovariectomized Rats Reham A
    Progress in Nutrition 2018; Vol. 20, N. 1: 86-93 DOI: 10.23751/pn.v20i1.5223 © Mattioli 1885 Original article Biological effect of calcium and vitamin D dietary supplements against osteoporosis in ovariectomized rats Reham A. Mustafa1, Nehal A. A. Alfky1, Haifa H. Hijazi1, Eslam A. Header1,2, Firas S. Azzeh1 1 Clinical Nutrition Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, KSA. - E-mail: [email protected]; 2Department of Nutrition and Food Science Faculty of Home Economics Minufiya University, Egypt. Summary. There is a direct association between the lack of estrogen and the progress of osteoporosis. This study was done to evaluate the biological effect of diet supplementation with calcium (Ca), and vitamin D (VD) on osteoporosis in ovariectomized (OVX) rats and to examine the possible potential mechanisms. Twenty-eight rats were randomly divided into 4 equal groups (n=7). To induce estrogen deficiency in rats, bilateral ovariectomy and sham (SHAM; negative control) surgery were done. In the basal diet, Ca and VD was supplemented with 210 mg/kg and 600 IU/kg, respectively, for 6 weeks. Alendronate as a standard anti- osteoporotic drug was used in a single weekly dose (3 mg/kg) for 6 weeks. After six weeks, serum markers of osteoporosis and bone femur status were evaluated. The results exposed that Ca and VD supplementation increased the body weight gain and diminished the uterine weight as a result of ovariectomy operation. These supplements significantly raised the serum Ca, bone-specific alkaline phosphatase, free thyroxin, and osteo- calcin in OVX-rats, while the serum interleukin-1beta, interleukin-6, parathormone, and pyridinoline levels were significantly dropped.
    [Show full text]
  • Dose-Dependent Effects of Salmon Calcitonin on Bone Turnover in Ovariectomized Rats
    East Tennessee State University Digital Commons @ East Tennessee State University Electronic Theses and Dissertations Student Works 12-2004 Dose-Dependent Effects of Salmon Calcitonin on Bone Turnover in Ovariectomized Rats. Beatrice H. Owens East Tennessee State University Follow this and additional works at: https://dc.etsu.edu/etd Part of the Medical Sciences Commons Recommended Citation Owens, Beatrice H., "Dose-Dependent Effects of Salmon Calcitonin on Bone Turnover in Ovariectomized Rats." (2004). Electronic Theses and Dissertations. Paper 977. https://dc.etsu.edu/etd/977 This Dissertation - Open Access is brought to you for free and open access by the Student Works at Digital Commons @ East Tennessee State University. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of Digital Commons @ East Tennessee State University. For more information, please contact [email protected]. Dose-dependent Effects of Salmon Calcitonin on Bone Turnover in Ovariectomized Rats _______________ A dissertation presented to the faculty of the Department of Anatomy and Cell Biology East Tennessee State University _______________ In partial fulfillment of the requirements for the degree Doctor of Philosophy in Biomedical Science _______________ by Beatrice H. Owens December 2004 ________________ Dr. Ronald C. Hamdy, Co-Chair Dr. Fred E. Hossler, Co-Chair Dr. Kenneth Ferslew Dr. Ellen Rasch Dr. Richard Skalko Keywords: bone formation, bone mineral density, bone resorption, bone turnover, calcitonin, osteoblasts, osteoclasts, osteoporosis, ovariectomy, remodeling Dose-dependent Effects of Salmon Calcitonin on Bone Turnover in Ovariectomized Rats by Beatrice H. Owens In the United States, osteoporosis results in about 1.5 million annual fractures, costing approximately $15 billion.
    [Show full text]
  • S12986-021-00602-Y.Pdf
    Mao et al. Nutr Metab (Lond) (2021) 18:76 https://doi.org/10.1186/s12986-021-00602-y RESEARCH Open Access Metabolomics and physiological analysis of the efect of calcium supplements on reducing bone loss in ovariectomized rats by increasing estradiol levels Hongmei Mao1, Wenjun Wang2, Lili Shi1, Chen Chen1, Chao Han1, Jinpeng Zhao1, Qin Zhuo1, Shi Shen1, Yan Li1* and Junsheng Huo1* Abstract Background: Data from the 2010–2012 Chinese National Nutrition and Health Survey showed that the vast majority of postmenopausal women in China had dual defciencies in calcium and estrogen. Objective: This study aimed to clarify whether calcium supplementation alleviated bone loss caused by calcium restriction combined with estrogen defciency in rats. Methods: Forty-eight female rats aged 9 weeks were assigned to 4 groups and fed a low-calcium diet: sham-oper- ated (SHAM-LC), ovariectomized (OVX-LC), and ovariectomized rats treated with 750 mg/kg (OVX-LC-M) or 2800 mg/ kg CaCO3 (OVX-LC-H). CaCO3 or distilled water was administered orally for 13 weeks. Bone mineral density (BMD) and histomorphometry of the femur, serum biochemical parameters, and serum metabolites were analyzed. Results: The OVX-LC rats showed a signifcant increase in body weight and serum levels of lipid markers, a signifcant decrease in serum estradiol, calcium, phosphorus, and 25(OH)D levels, and deterioration of the femur. At 750 mg/ kg and 2800 mg/kg, CaCO3 reduced the deterioration of trabecular bone and increased the trabecular area percent- age (Tb.Ar %) and BMD of the femur. Serum estradiol levels increased in a dose-dependent manner after CaCO3 supplementation (p < 0.01).
    [Show full text]